GlycoVaxyn Appoints Philippe Dro as CEO

21-May-2008
GlycoVaxyn AG announced the appointment of Dr Philippe Dro as Chief Executive Officer and member of the Supervisory Board. Dr Dro brings to GlycoVaxyn nearly 20 years entrepreneurial experience in the life science industry, including playing a pivotal role in executing strategic transactions at several biotech/medtech companies. Most recently, Dr Dro was Chairman and CEO of Endoart SA, a medtech company developing telemetric driven implants for cardiac disease and obesity, that was sold to Allergan, Inc. Dr Dro spearheaded the transformation of Endoart from a distressed position to one that commanded a cash price of CHF 120 million. From 1999 to 2003, Dr Dro was Chief Operating Officer (COO) and part of the founding team of AXOVAN AG, a GPCR focused drug discovery company, that grew the company to a clinical-stage entity which was acquired by Actelion Ltd for CHF 252 million. Prior to this, Dr Dro held the position of COO and director of the Board of Antares Pharma, Inc (AMEX: AIS), a drug delivery company formed by the merger of Permatec Group and Mediject, Inc. Dr Dro also held executive director positions at Skyepharma Ltd during its listing on the LSE and in finance at Sandoz Pharma AG (now Novartis). Dr Dro earned a Pharm D from University of Grenoble (France) and an MBA jointly from Ecole Supérieure de Commerce de Lyon (France) and Cranfield School of Management (UK).

Other news from the department manufacturing

Most read news

More news from our other portals

Fighting cancer: latest developments and advances